EMILIO
ESTEBAN GONZALEZ
Profesor Titular de Universidad
Hospital Clinic Barcelona
Barcelona, EspañaPublications in collaboration with researchers from Hospital Clinic Barcelona (15)
2020
-
ASTRIS, a large real-world study to evaluate the efficacy of osimertinib in epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer patients: Clinical characteristics and genotyping methods in a Spanish cohort
Revista Espanola de Patologia, Vol. 53, Núm. 3, pp. 140-148
2018
-
Preliminary safety results of the randomized phase II ABIDO-SOGUG trial: Toxicity profile of concomitant abiraterone acetate + docetaxel treatment in comparison to docetaxel
Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii286
-
Radium-223 international early access program: Results from the Spanish subset
Future Oncology, Vol. 14, Núm. 1, pp. 41-50
2016
2015
-
Chemotherapy-associated anemia in patients with lung cancer: An epidemiological, retrospective and multicenter study
Future Oncology, Vol. 11, Núm. 11, pp. 1665-1674
-
Management of the adverse events of afatinib: A consensus of the recommendations of the Spanish expert panel
Future Oncology, Vol. 11, Núm. 2, pp. 267-277
2014
2013
-
Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The TUGAMO study
British Journal of Cancer, Vol. 109, Núm. 1, pp. 121-130
-
Dolor como factor predictor de depresión en el paciente oncológico: estudio de casos y controles. Estudio D-PRESS
Revista de la Sociedad Espanola del Dolor, Vol. 20, Núm. 3, pp. 113-121
-
Prospective study assessing hypoxia-related proteins as markers for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinoma
Annals of Oncology, Vol. 24, Núm. 9, pp. 2409-2414
-
Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO study
British Journal of Cancer, Vol. 108, Núm. 12, pp. 2565-2572
2011
-
Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: A multicentre, observational, prospective study
The Lancet Oncology, Vol. 12, Núm. 12, pp. 1143-1150
2007
-
Phase II study with the combination of gemcitabine and DTIC in patients with advanced soft tissue sarcomas
Cancer Chemotherapy and Pharmacology, Vol. 59, Núm. 2, pp. 251-259
2006
-
Phase I/II trial of doxorubicin and fixed dose-rate infusion gemcitabine in advanced soft tissue sarcomas: A GEIS study
British Journal of Cancer, Vol. 94, Núm. 12, pp. 1797-1802
2000
-
Tumor markers at the time of recurrence in patients with germ cell tumors
Cancer, Vol. 88, Núm. 1, pp. 162-168